Home LiteratureArticle Details

PMID: 23712183 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Comment

Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?

Nature reviews. Clinical oncology ·Vol. 10 ·No. 7 ·2013-07-00 ·Pages 372-4

Michieli P, Di Nicolantonio F

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents/pharmacology Cell Proliferation/drug effects Humans Proto-Oncogene Proteins c-met/antagonists & inhibitors,metabolism Pyrrolidinones/pharmacology Quinolines/pharmacology Tubulin Modulators/pharmacology

Chemicals

Antineoplastic Agents Pyrrolidinones Quinolines Tubulin Modulators Proto-Oncogene Proteins c-met

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Michieli Paolo

Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy. paolo.michieli@ircc.it

Di Nicolantonio Federica

References (9)

9 references, click to expand

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Clin Cancer Res. 2012 Mar 15;18(6):1655-62 PMID: 22291137
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.
J Clin Oncol. 2011 Apr 1;29(10):1271-9 PMID: 21383285
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
Cancer Res. 2013 May 15;73(10):3087-96 PMID: 23598276
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197.
J Biol Chem. 2011 Jun 10;286(23):20666-76 PMID: 21454604
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Lancet Oncol. 2013 Jan;14(1):55-63 PMID: 23182627
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
Mol Cancer Ther. 2010 Jun;9(6):1544-53 PMID: 20484018
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
J Clin Oncol. 2011 Aug 20;29(24):3307-15 PMID: 21768463
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Clin Cancer Res. 2012 Jan 15;18(2):510-23 PMID: 22128301
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
Clin Cancer Res. 2013 May 1;19(9):2381-92 PMID: 23532890

Article Info

Journal

Nature reviews. Clinical oncology

Abbr.

Nat Rev Clin Oncol

ISSN

1759-4782

DOI

10.1038/nrclinonc.2013.86

paolo.michieli@ircc.it

Published

2013-07-00

Epub

2013-00-28

Pages

372-4

Language

English

Region

England

NLM ID

101500077

Subset

Corrections

CommentOn

PMID: 23532890

CommentOn

PMID: 23598276

External Links

PubMed source DOI: 10.1038/nrclinonc.2013.86 View journal details

Analysis Services

Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?

Contact

WeChat Official Account